MedTrace Logo

PAH Exercise Study

NCT06941441 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2025-04-23

No results posted yet for this study

Summary

Ten patients with PAH who are stable and eligible to initiate sotatercept therapy will participate in a 26 week study that consists of a 24-week intervention period where patients will receive complimentary sotatercept as prescribed, plus a tailored, progressive home exercise program with wrist-worn fitness tracker and oxygen saturation monitoring.

Conditions

  • Pulmonary Arterial Hypertension (PAH)
  • Exercise Therapy

Interventions

OTHER

Home exercise program

A tailored, progressive home exercise program with wrist-worn fitness tracker and oxygen saturation monitoring

Sponsors & Collaborators

Principal Investigators

  • Mary Beth Brown, PT, PhD · University of Washington

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-04-15
Primary Completion
2026-09-30
Completion
2026-09-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06941441 on ClinicalTrials.gov